

Roche launches Ocrevus to redefine Multiple Sclerosis treatment in India

27 February 2024 | News

First and only approved High efficacy therapy with more than 300000+ patients treated globally



Roche Pharma India has announced the launch of its blockbuster breakthrough drug, Ocrevus (Ocrelizumab), for the treatment of multiple sclerosis (MS), expanding its neurology portfolio to cater to unmet needs of numerous patients grappling with this debilitating disease in India.

The majority of individuals are diagnosed with multiple sclerosis between the ages of 20 and 40, making the disease a leading cause of non-traumatic disability in younger adults.

It is the only monoclonal antibody drug approved for the treatment of both relapsing remitting (RRMS) and primary progressive (PPMS) with more than 10 years of clinical and real world data. Over 80% of people with RRMS and over 33% of people with PPMS treated with Ocrevus showed no signs of disability progression.

Starting Ocrevus two years earlier saved almost 10 years of disease progression in people with RRMS. 92% of people with RRMS who received Ocrevus earlier, did not need a walking aid; and 80% of people with PPMS did not require a wheelchair after 10 years of initiating and continuous therapy with Ocrevus.

Ocrevus is Roche's leading product globally and is currently available in 100+ countries. In India, the product is approved for both relapsing and primary progressive forms of multiple sclerosis.